Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Michiko, Just a hopeful guess, nothing more...it certainly could take longer but what they've accomplished thus far without alot of $$$ or employees is astonishing to say the least.
DNAP Speculation:
Obstacles: Float, LaJolla deal and dilution, Naked shorting and other sketchiness regarding virtually all OTC stocks.
Positives: Unique Technology growing more advanced every month. Products ideally suited for 3 parallel fields. Potential to win patents assuring a large share in the emerging personalized medicine revolution.
Timeline Speculation:
Sept: PRs detailing Moffitt clinical trials (can be done very quickly or even retrospectively) .02
Oct: Nothing substantial .013-.022
Nove: Ovanome released .02-.10
Dec: Patent 1 awarded .06-.12
Jan; Another patent .11-.16
feb: Statinome, get out of La Jolla deal .09--.31
Mar: BP, cardiac meds classifiers .18-.76
Apr: Details of initiatives with Moffitt, IBM Life Sciences, Affymmetrix, Stanford, Duke .38-1.25
May: ?????
TrustedByNobody (TDiamonds) picks very interesting times to show up and then just disappears into thin air. Priceless.
Evryone on this board interested in discussing the company-----Please do everyone a favor and STOP responding to TBM (Tdiamonds). You only encourage him and direct attention to him....and away from the companies accomplishments....his obvious goal
Hugewin
Mingwan,
Good point. I hadn't thought of the fact that we will be able to access info about the trials soon enough. Exciting stuff. Even a few classifiers would mean big news in the medical community and a name in the field!
Carter
Forgot to add that IF DnaPrint gets the necessary patents to protect their technique and is successful in the first several classifiers (they need this to get more funding), they could make classifiers for just about evry CV, chemo, allergy, reflux, asthma, pain, anti-inflammatory cuurently on the market over the next several years unless someone else finds a way to do it another way. Likely competitors would be Big Pharma (who has no real incentive to compete). Being a pioneer is fraught with difficulties but the rewards are massive.
Go ahead and become a drug company but first things first.
I disagree with the notion that drug classifiers cannot make alot of money. I do agree that the revenue from a single classifier test (done once per Pt) cannot compare to the huge $$ from someone using your product multiple times/day for months or years like drugs. However, the amount of pts who could benefit from the classifier is huge. In the outpatient setting, imagine a $100 test that could choose the best HTN med for an individual Pt. Another that could do the same for Statins. Ins would likely cover it if costs are not too outrageous b/c it 'll save them alot of money realted to trial and error and decreased future events related to side effects and poor outcomes. These tests, if proven beyond a doubt, could become the standard of care
Cardiovascular Drugs of importance:
Pretty interesting list Mingwan
I hope they are not testing for responsiveness to mannitol yet (rarely used and not really a CV drug) , sulfonamide (antibiotic), or even spironolactone (used to spare loss of K from kidneys when given another diuretic). In their place I'd like to see:
1) aspirin. This is of great importance as up to 30% of people are not believed to respond appropriately and it is used by a large proportion of cardiac and other Pts. A test would be highly applicable and probably readily accepted with proof
2) Lasix. This may have been what you meant with 'sulfonamide'. It's primarily an acute diuretic often used for heart failure and pulm edema
3) Clopidrogel. Another anti-platelet agent like aspirin used for atherosclerosis and thought to prevent strokes and MIs
4) Multiple other B-blockers (including labetolol) would be nice also
5) Angiotensin receptor blockers (similar to ace inhibitors) and used for HTN, etc
Imagine the implications if this collaboration is able to produce effective classifiers for 1) statins 2) antiplatelet agents and 3) HTN meds. It may be cost effective to use one or more of these tests for everyone with obesity, diabetes, HTN, tobacco abuse, hypercholesterolemia, family history heart disease/stroke or any other risk factors. Just about anyone in the US over age 45 is on one or more of these meds. IF IT WORKS, monumental changes will ensue and patients will receive better care.
Next stop: Meds for Type II diabetes (glucophage, metformin, etc), proton pump inhibitors (prilosec, prevacid, etc), antihistamines (clarinex, allegra, zyrtec, etc)
Exciting. Carter
Hedge Fund manipulation of DNAP. RB boards: Tdiamonds, spook, lizard likely involved. New SEC rules will allow DNAP to be naked shorted with impunity until early 2005 atleast. Any predictions on whether the company will survive thi assault?
What can DNAP do to remedy this?
Carter
(Hugewin)
Somebody please explain the problems, if any, with the LaJolla financing.
Retro,
Thanks for the reply. I just wonder why anyone would spend so much time and effort bashing a stock unless they had a financial incentive.
Here's a post of mine on RB (Hugewin over there) with no responses. Anyone have an answer to these ??s over here?
Why bash a penny stock so hard? Why spend so much time here if you are not interested in the company? I can think of only a couple reasons:
1) Influence share price so can make $$ by shorting
2) Lower share price to load up on the stock
3) Absolutely no life whatsoever
BTW, DNAP is in a better position right now than they ever have been before. It's still early in the game but the collaboration with Moffit (and likely with the US govt in my opinion) coupled with the LaJolla financing to screen the pharmoacogenomic platform for a dozen or so other drug responders will pay off big time. It's never easy to be the first! Just my opinion.
Anyone care to comment on whether or not consistent bashing actually lowers the pps.
(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy)
CARTER
Terry, Studies and discussions like this make the mind spin. Nature vs. Nurture, predestination, free will, religion/philosophy, "evil" vs. "good"........What is the role of the criminal justice system? Is it to protect society? With ability to predict predisposition to certain behaviours (which will assuredly happen within 2-3 decades), might the focus of the criminal justice system be redirected at prevention and rehabilitation rather than punishment.
Terry,
I agree it's probably not possible or maybe even ethical at this time. However, I remember seeing a study a couple years ago linking antisocisal personality disorder to a single gene variant. If I remember correctly about 85% of people with this gene variant WHO HAD BEEN PHYSICALLY, EMOTIONALLY, or SEXUALLY ABUSED AS A CHILD displayed the classic characteristics of ASPD- violent tendencies, lack of conscience, charisma, and tendency to abuse others. I actually hope it's not being developed as the controversy could take away from more important technology and it may be a little redundant at the scene of a rape or murder. See below
http://asperdis.org/Severe%20(Antisocial)%20Personality%20Disorder%20Causes%20&%20diagnosis.htm
Maha,
Yes, in the Sarasota article the only 2 pieces of info that were given include 1) white male and 2) antisocial personality disorder (commonly known as a sociopath or psychopath) ,that's exactly what they described in the vague wording. Antisocial P.D. could possibly be inferred genetically as there is a significant genetic predisposition, especially when combined with early childhood abuse. Could DNAP have added this?
DNAP PPS Predictions by month
Highs for each month
4/04 .05
5/04 .047
6/04 .045
7/04 .056
8/04 .062
9/04 .078
10/04 .11
11/04 .21
12/04 .18
1/05 .36
......6/05 .75
6/06 1.90
12/06 5.00
12/07 14.00
A couple granted patents couldn't hurt either
Agreed cowboyd. I think DNAP will bounce from low threes to low fours until this fall then move up sharply with early moffit results and never look back. Look for .40-.60 range by this time next year.
OVANOME/STATNOME
Could anyone provide a link or otherwise share some information about accuracy/sensitivity/specificity of OVANOME or STATNOME? I'm having a hard time finding anything too convincing but am hopeful one of these will get DNAP moving. Thanks